Tevimbra plus chemotherapy improved overall survival in patients with advanced ESCC, with 68.3% achieving a response. Median time to response was 6.1 weeks, with most responses occurring within eight ...

Get Instant Summarized Text (Gist) A new approach, PERISCOPE, integrates Cell Painting and Optical Pooled Screening to enable genome-scale CRISPR screens, linking cell morphology to gene function ...

Jones, a USC commit, is one of the top players to watch in the CCL/ESCC in 2025. (Tony Gadomski/Tony Gadomski for Shaw Local News Network) The CCL/ESCC Class of 2025 featured plenty of talented ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus chemotherapy between early and late responders with ESCC. Patients with locally ...

The results come from the phase 3 SCIENCE trial (NCT05244798), which included 146 patients with previously untreated, locally advanced ESCC. The patients were randomly assigned to receive 1 of 3 ...

Evolution is the basis of biological diversity, driven by mechanisms that allow organisms to adapt and survive. One such mechanism is polyploidy, where organisms carry extra copies of their genomes.

177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase I drugs for Esophageal Squamous ...

GENETIC researchers in Barcelona have reached a historic milestone, creating the very first map of the spliceosome. A key part of interpreting DNA, the spliceosome helps cells to interpret and ...

Background: Globally, esophageal squamous cell carcinoma (ESCC) stands out as a common cancer type, characterized by its notably high rates of occurrence and mortality. Recent advancements in ...

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in the world, with a high rate of morbidity. The invasion and metastasis of ESCC is the main reason for high mortality. More ...